About

These allow the patient to reduce the total volume of gel applied by about half compared with a 1% gel. Gels with a higher concentration of testosterone are not yet available in the US, but a 2% testosterone gel is available in the EU (81,82). The scrotum has approximately a 40-fold higher rate of absorption than the forearm and the first testosterone patches were placed on the scrotum, but these are not so popular because the scrotum has to be shaved and the adherence is not so good. This is a depot preparation that requires only four injections a year (80) and has a superior pharmacokinetic profile compared with the other injectable testosterone formulations. A long-lasting formulation of testosterone undecanoate, another testosterone ester, is available in the EU and other countries, but not yet in the US. have been undertaken on the relationship between more general aggressive behavior, and feelings, and testosterone. This increases the reproductive fitness of the parents because their offspring are more likely to survive and reproduce.|Low testosterone concentrations are known to occur in association with type 2 diabetes. The relationship between testosterone and HDL is confounded by the fact that both HDL and testosterone are inversely related to BMI. However, when given as a transdermal gel to hypogonadal men, there is either no significant change or only minor changes in HDL levels (28,31,32). Vascular tissue (including endothelium and vascular smooth muscle cells) contains androgen receptors, so it is to be expected that testosterone (or its metabolite, oestrogen) is likely to affect the cardiovascular system. There appears to be no consistent evidence that the prevalence of hypogonadism differs between racial and ethnic groups (24–26). Likewise, measurement of symptoms alone is not reliable, as hypogonadal symptoms are non-specific. In the Baltimore Longitudinal Study on Ageing, it was found that 19% of men over 60 years had low testosterone.|Combined therapy with Continuous Positive Airway Pressure (CPAP) and testosterone gel was more effective than CPAP alone in the treatment of obstructive sleep apnoea . In most cases, discontinuation of testosterone therapy is not required.There is no evidence that testosterone therapy can result in onset or worsening of sleep apnoea. A meta-analysis of RCTs of testosterone therapy reported that venous thromboembolism was frequently related to underlying undiagnosed thrombophilia-hypofibrinolysis disorders . Any elevation above the normal range for haematocrit usually becomes evident between three and 12 months after testosterone therapy initiation. An interesting observation is that untreated hypogonadism increased the re-admission and mortality rate in men with heart failure .|Male hypogonadism is a clinical syndrome which comprises of symptoms with or without signs and biochemical evidence of testosterone deficiency. But hormone replacement therapy helps improve sex drive, symptoms of depression and energy levels. Most males with symptoms of low testosterone don’t have a problem with their pituitary glands or testicles. Providers call it male hypogonadism when you have symptoms along with these low levels. There is evidence, however, that testosterone will stimulate the growth of existing prostatic cancers and, of course, existing prostate cancer is contraindicated for testosterone therapy (4). Prostate volume does, however, increase during testosterone therapy usually in the first 6 months, but this is usually to the normal volume seen in eugonadal men.|Interestingly, this latter meta-analysis has provided novel evidence that the role of testosterone on bone mineral density was even higher in patients with diabetes , who are themselves at a higher risk of hypogonadism and bone fracture 40,122,123. In line with these data, the results derived from the T4DM study showed that a combination of lifestyle and testosterone therapy can reduce the incidence of T2DM at follow-up . A meta-analysis including 17 RCTs specifically investigated the role of testosterone therapy on several metabolic parameters in patients with T2DM and/or MetS . Some published data have suggested that testosterone therapy reduces body fat percentage and increases lean mass . Although meta-analyses suggest a significant effect of testosterone therapy over placebo, the magnitude is low and the heterogeneity high, therefore reducing the scientific value of the effect 97,111.The role of testosterone therapy in patients with cognitive impairment is even more uncertain. Findings from the TRAVERSE trial showed that testosterone therapy alone did not appear to represent an effective treatment option for most men with clinical depressive disorders .Robust data on the effect of testosterone therapy on QoL are limited.}
Accordingly, it has been reported that measuring circulating testosterone levels under non-fasting conditions can result in an underestimation of total testosterone by more than 30% of its true value . Although these case-history tools have demonstrated clinical utility in supporting the biochemical diagnosis of hypogonadism, or in the assessment of testosterone therapy outcomes, their specificity remains poor and they should not be used for systematic screening of men with hypogonadism . A longitudinal evaluation study showed that during the recovery phase, a further improvement of testosterone levels can be observed up to 12 months after COVID-19. Studies evaluating patients in the recovery phase of COVID-19 have documented either restored 55,56 or persistently low testosterone levels in the majority of cases .
It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful. Decline of testosterone production with age has led to interest in androgen replacement therapy. As demonstrated by a meta-analysis, substitution therapy with testosterone results in a significant reduction of inflammatory markers. These include adult-type body odor, increased oiliness of skin and hair, acne, pubarche (appearance of pubic hair), axillary hair (armpit hair), growth spurt, accelerated bone maturation, and facial hair. The male brain is masculinized by the aromatization of testosterone into estradiol, which crosses the blood–brain barrier and enters the male brain, whereas female fetuses have α-fetoprotein, which binds the estrogen so that female brains are not affected. Among women with congenital adrenal hyperplasia, a male-typical play in childhood correlated with reduced satisfaction with the female gender and reduced heterosexual interest in adulthood. Specifically, testosterone, along with anti-Müllerian hormone (AMH) promote growth of the Wolffian duct and degeneration of the Müllerian duct respectively.
Diagnosis of the condition requires the presence of low serum testosterone levels and the presence of hypogonadal symptoms. The main symptoms of hypogonadism are reduced libido/erectile dysfunction, reduced muscle mass and strength, increased adiposity, osteoporosis/low bone mass, depressed mood and fatigue. In the Asia-Pacific region, Japan and China are expected to show rapid growth as awareness and acceptance of testosterone therapy rise. Leading in market share due to increasing awareness of low testosterone levels among aging populations.
The brain is also affected by this sexual differentiation; the enzyme aromatase converts testosterone into estradiol that is responsible for masculinization of the brain in male mice. Adult testosterone effects are more clearly demonstrable in males than in females, but are likely important to both sexes. Pubertal effects begin to occur when androgen has been higher than normal adult female levels for months or years.
This isn't just a test for those trying to conceive; it's a fundamental window into the pituitary gland's command center and its direct line to your vitality. One survey in the United Kingdom found that while the majority of people with KS identify as male, a significant number have a different gender identity. However, it is estimated that only 25% of the individuals with Klinefelter syndrome are diagnosed throughout their lives. The classification of Klinefelter syndrome as an intersex variation is debated. In August 2022, a team of scientists published a study of a skeleton found in Bragança, north-eastern Portugal, of a man who died around 1000 AD and was discovered by their investigations to have a 47,XXY karyotype. In 1956, Klinefelter syndrome was found to result from an extra chromosome. Considering the names of all three researchers, it is sometimes also called Klinefelter–Reifenstein–Albright syndrome.

Female